VenX, the medical device company backed by TNInvestco TriStar Technology Fund in Nashville, announced 18 July it recently received the FDA's 510(k) pre-market notification for its Revolution device for treating spider and reticular vein conditions.
With that hurdle surmounted, the company is "completing our final clinical trials and working towards launching the product,” said VenX President and CEO Navroze Mehta in a release.
The VenX website says the company's technology and technique involve a "nanophlebectomy," which entails piercing the affected vein in a manner that triggers a wound-healing response and the resolution of the prior problem.
VenX has received at least $550,000 investment from TriStar Technology Fund, which is the TNInvestco-certified fund created by TriStar Technology Ventures, based in Nashville.
TriStar was founded by Vanderbilt University Vice Chancellor Emeritus Harry Jacobson, M.D., along with Christopher Rand and Brian Laden, Ph.D., both of whom were previously executives within Vanderbilt University's office of technology transfer and enterprise development. The full amount of investment by the founders and other investors, if any, has not been disclosed.
Development of the device was led by Dr. Edward Boyle and Dr. Andrew Jones, who are associated with Inovia Vein Specialty Center at Bend, Oregon; they collaborated with clinical and design specialists to create the device, which is used to "treat and eliminate spider and reticular veins in a transdermal fashion," the company said. The full VenX release is here. VNC